Tech Company Financing Transactions
Spiral Therapeutics Funding Round
Spiral Therapeutics closed a $8.3 million funding round on 1/9/2023. Investors included Catalio Capital Management, Savoir Capital and Humboldt Fund.
Transaction Overview
Company Name
Announced On
1/9/2023
Transaction Type
Venture Equity
Amount
$8,250,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds for the continuing development of its lead candidate, SPT-2101, for the treatment of inner ear inflammation.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6000 Shoreline Ct, Suite 206, South
San Francisco,, CA 94080
USA
San Francisco,, CA 94080
USA
Phone
Website
Email Address
Overview
Spiral is advancing a therapeutic pipeline with focus on balance disorders and hearing loss. Our lead program, SPT-2101, is a sustained-release steroid formulation for the treatment of Ménière's disease. 40 million people in the US qualify for hearing loss treatment, but there are no drugs approved for hearing loss. Drug delivery to the inner ear remains the largest obstacle. Precise, non-invasive placement techniques, combined with long-acting delivery systems have the potential to overcome the barriers of drug delivery to the inner ear.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Hugo Peris
Chief Financial Officer
Kyle Peterson
Chief Medical Officer
Charles Limb
Chief Scientific Officer
Signe Erickson
Browse more venture capital transactions:
Prev: 1/9/2023: Qritive venture capital transaction
Next: 1/9/2023: Oxford Ionics venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs